Our Blog
-
BioUtah Letter on Prioritizing Life Sciences Workers for Vaccine Distribution
December 3, 2020 Mr. Rich Lakin, MSPH, MPA Immunizations Director Utah Department of Health Bureau of Epidemiology PO…
-
ProLung Has a New Name, Gets $3.3 Million Private Placement and More…
ProLung, now IONIQ Sciences (IONIQ), has been on a roll! Last week, the company announced that they had fully…
-
ARUP Advocates for the RESULTS Act To Protect Patient Access to Critical Laboratory Testing Services
SALT LAKE CITY, November 19, 2025— With a deadline approaching on January 31, 2026, ARUP Laboratories has joined…
-
Recap: 2025 Mayer Brown Utah Life Sciences Summit
The 2025 BioUtah Utah Life Sciences Summit (ULSS) took place November 12 at the Hilton Salt Lake City…
-
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test.
-
New Preclinical Study Demonstrates Feasibility of Microbubble-Mediated, Non-Thermal Focused Ultrasound for Brain Tumor Ablation
Salt Lake City, UT –Wednesday November, 5th 2025— Researchers from the University of Utah and Microvascular Therapeutics (MVT)…
-
Owlet Partners with Rhapsody to Connect Remote Baby Monitoring Data to EHRs
Collaboration bridges home and hospital, creating a secure pathway for pediatric insights to be managed and shared.
-
J3 Bioscience Announces Collaboration to Study LIV-Ring VR101 for Cancer-Therapy–Related Vaginal Dryness
Investigator-Initiated, grant-supported pilot study evaluating a novel non-prescription therapy for cancer-related vaginal dryness.
-
2025 BioUtah Life Sciences Awards Presented at the Mayer Brown Utah Life Sciences Summit
BioUtah will honor outstanding leaders in Utah’s life sciences community with five awards recognizing contributions to the industry.
-
PhotoPharmics Surpasses Enrollment Target with 350 Participants in First-of-a-Kind Remote, Home-Based Phase 3 “Light for PD” Clinical Trial
PhotoPharmics Surpasses Enrollment Target with 350 Participants in First-of-a-Kind Remote, Home-Based Phase 3 “Light for PD” Clinical Trial
-
Merit Medical Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (AVF) Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial
The target lesion primary patency (TLPP)1 and access circuit primary patency (ACPP)2 of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)…